美多巴与多巴胺受体激动剂合用治疗帕金森病的效果分析

Analysis of the efficacy of madopa combined with dopamine receptor agonists in the treatment of patients with Parkinson's disease

目的:比较在帕金森病患者临床治疗中实施单用美多巴和美多巴与多巴胺受体激动剂合用的治疗效果。方法:2014年1月-2019年1月收治帕金森病患者30例,随机分为两组,各15例。对照组单用美多巴治疗;试验给予美多巴与多巴胺受体激动剂联合治疗。比较两组临床疗效、日常生活能力、运动功能、相关并发症等临床指标的改善情况。结果:试验组治疗后UPDRSⅡ(日常活动)、UPDRSⅢ(运动功能)、UPDRSⅣ(治疗的并发症)等指标得分情况均显著优于对照组,差异有统计学意义(P<0.05);试验组治疗总有效率显著高于对照组,差异有统计学意义(P<0.05)。结论:与单用美多巴治疗相比,将美多巴联合多巴胺受体激动剂用于帕金森病的治疗中,能显著改善临床治疗效果,提升治疗安全性。

Objective:To compare the therapeutic effects of madopa alone and madopa combined with dopamine receptor agonists in the clinical treatment of patients with Parkinson's disease(PD).Methods:From January 2014 to January 2019,30 patients with Parkinson's disease were selected,they were randomly divided into the two groups with 15 cases in each group.The control group was treated with madopa alone.The experiment group was treated with madopa combined with dopamine receptor agonist.The improvement of clinical efficacy,activities of daily living,motor function and related complications were compared between the two groups.Results:After treatment,the scores of UPDRSⅡ(daily activity),UPDRSⅢ(motor function)and UPDRSⅣ(complications of treatment)in the experiment group were significantly better than those in the control group,the difference was statistically significant(P<0.05).The total effective rate of the experiment group was significantly higher than that in the control group,the difference was statistically significant(P<0.05).Conclusion:Compared with madopa alone,the use of madopa combined with dopamine receptor agonists in the treatment of Parkinson's disease can significantly improve the clinical efficacy and safety of Parkinson's disease.